PharmaShots | Incisive News in 3 Shots

Subscribe Now

Myeloma

$Sanofi's Sarclisa (isatuximab) Receives EC's Approval for adults with Relapsed and Refractory Multiple Myeloma$

Sanofi's Sarclisa (isatuximab) Receives EC's Approval for adults with Relapsed and Refractory Multiple Myeloma

April 19, 2021

Janssen Initiates Rolling Submission of BLA to US FDA of Autoleucel (cilta-cel) to Treat Multiple Myeloma

Janssen Initiates Rolling Submission of BLA to US FDA of Autoleucel (cilta-cel) to Treat Multiple Myeloma

December 23, 2020

$GSK's Belantamab Mafodotin Receives the US FDA Advisory Committee's Recommendation to Treat Relapsed/Refractory Multiple Myeloma$

GSK's Belantamab Mafodotin Receives the US FDA Advisory Committee's Recommendation to Treat Relapsed/Refractory Multiple Myeloma

July 15, 2020

$GSK Reports EMA's Acceptance of MAA for Belantamab Mafodotin to Treat Relapsed or Refractory Multiple Myeloma$

GSK Reports EMA's Acceptance of MAA for Belantamab Mafodotin to Treat Relapsed or Refractory Multiple Myeloma

February 4, 2020

Genmab's Darzalex (daratumumab) Split Dosing Regimen Receives the US FDA Approval for Multiple Myeloma

Genmab's Darzalex (daratumumab) Split Dosing Regimen Receives the US FDA Approval for Multiple Myeloma

February 12, 2019

J&J acquired global co-development and Commercialization rights of experimental myeloma gene therapy from a Chinese Start-up Nanjing Legend Biotechnology

J&J acquired global co-development and Commercialization rights of experimental myeloma gene therapy from a Chinese Start-up N...

August 6, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us